- Includes scale-up and GMP manufacturing of drugs in late-stage development
- Antibody targets advanced, refractory brain tumors in pediatric patients
DARMSTADT, Germany, Aug. 1, 2016 /PRNewswire/ -- Merck [http://www.merckgroup.com/en/index.html], a leading science and technology company, will provide its Provantage(®) End-to-End development and manufacturing services to Y-mAbs Therapeutics, Inc. in support of Y-mAbs' monoclonal antibody in late stage clinical development.
Photo - http://photos.prnewswire.com/prnh/20160727/393609 [http://photos.prnewswire.com/prnh/20160727/393609]
The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs' lead cell line to Merck, services will include scale-up and GMP manufacturing of an antibody currently in late stage clinical development.
"Pediatric brain cancer is an especially challenging therapeutic area that comes with an extreme sense of urgency," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science [http://www.merckgroup.com/en/products/life_science/life_science.html]. "Through our Provantage(®) services, which offer a templated, nimble approach to development and manufacturing, we expect to accelerate progress of this innovative therapeutic for patients in need."
"Through our agreement with Merck, Y-mAbs takes a major step towards our commitment of making these breakthrough pediatric treatments available to children with advanced and life-threatening cancers," said Thomas Gad, Y-mAbs' Founder, President and Head of Business Development and Strategy. "We expect to take delivery of cGMP drug product for our planned clinical trials by first half of 2017, and we are committed to making this leading immunotherapy product available to patients with life-threatening diseases worldwide."
Merck's Provantage(®) End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate the progression of molecules into the clinic and toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe [http://www.merckgroup.com/subscribe] to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of EUR 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merck-to-provide-provantage-end-to-end-development-and-manufacturing-services-to-y-mabs-for-lead-antibody-compound-300305273.html [http://www.prnewswire.com/news-releases/merck-to-provide-provantage-end-to-end-development-and-manufacturing-services-to-y-mabs-for-lead-antibody-compound-300305273.html]
CONTACT: Karen Tiano, +1 978 495 0093
Web site: http://www.merckgroup.com/